| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
32,560 |
23,498 |
$986K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
2,184 |
1,949 |
$183K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,951 |
3,316 |
$148K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
7,507 |
2,349 |
$140K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,984 |
3,311 |
$136K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
8,093 |
6,307 |
$132K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
1,862 |
1,665 |
$127K |
| 99497 |
|
2,803 |
2,468 |
$122K |
| 99223 |
Prolong inpt eval add15 m |
2,093 |
1,718 |
$117K |
| 71046 |
Radiologic examination, chest; 2 views |
6,069 |
5,102 |
$100K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
3,350 |
2,773 |
$93K |
| 99222 |
Initial hospital care, per day, moderate complexity |
1,131 |
1,005 |
$61K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
4,408 |
1,429 |
$56K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,522 |
1,323 |
$48K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
604 |
547 |
$46K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,709 |
1,642 |
$46K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,753 |
3,328 |
$45K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
612 |
532 |
$39K |
| 74018 |
|
2,147 |
1,884 |
$34K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
424 |
361 |
$31K |
| 93000 |
|
2,200 |
1,886 |
$31K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
702 |
576 |
$25K |
| 99442 |
|
856 |
673 |
$23K |
| 72100 |
|
1,055 |
952 |
$22K |
| 99406 |
|
2,384 |
1,936 |
$19K |
| 99307 |
|
3,030 |
2,414 |
$18K |
| 93922 |
|
706 |
597 |
$18K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
274 |
246 |
$17K |
| 80305 |
|
1,936 |
1,656 |
$17K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,045 |
983 |
$15K |
| 90756 |
|
650 |
589 |
$12K |
| 70210 |
|
548 |
487 |
$10K |
| 76775 |
|
323 |
255 |
$9K |
| 72040 |
|
432 |
388 |
$8K |
| 90674 |
|
486 |
394 |
$8K |
| 77080 |
|
119 |
108 |
$7K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,149 |
954 |
$7K |
| 99215 |
Prolong outpt/office vis |
86 |
74 |
$5K |
| 82962 |
|
2,161 |
1,572 |
$5K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
225 |
198 |
$4K |
| 92250 |
|
171 |
147 |
$4K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
668 |
527 |
$4K |
| 73560 |
|
209 |
171 |
$4K |
| 94060 |
|
109 |
102 |
$4K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
2,388 |
2,100 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
295 |
248 |
$4K |
| 90686 |
|
189 |
182 |
$3K |
| 81002 |
|
2,360 |
2,035 |
$2K |
| 80053 |
Comprehensive metabolic panel |
309 |
279 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,516 |
1,227 |
$2K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
1,360 |
1,107 |
$2K |
| 73630 |
|
85 |
77 |
$2K |
| 73030 |
|
76 |
68 |
$1K |
| 90661 |
|
31 |
30 |
$930.19 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
14 |
13 |
$785.80 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
25 |
12 |
$703.22 |
| G0008 |
Administration of influenza virus vaccine |
268 |
210 |
$556.68 |
| 87807 |
|
39 |
31 |
$400.11 |
| 82043 |
|
59 |
55 |
$260.06 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
287 |
182 |
$191.10 |
| 86308 |
|
24 |
21 |
$112.18 |
| 3078F |
|
10,351 |
8,358 |
$34.87 |
| 1125F |
|
7,202 |
5,830 |
$28.39 |
| 3074F |
|
8,477 |
6,972 |
$27.46 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
16 |
15 |
$23.96 |
| 1126F |
|
4,496 |
3,970 |
$19.68 |
| 3044F |
|
2,487 |
2,406 |
$10.58 |
| 3075F |
|
2,588 |
2,234 |
$9.74 |
| 3077F |
|
1,273 |
1,101 |
$4.44 |
| 3079F |
|
1,313 |
1,166 |
$4.35 |
| 3066F |
|
2,009 |
1,569 |
$2.59 |
| 3061F |
|
816 |
784 |
$1.64 |
| 3080F |
|
346 |
299 |
$1.11 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
14 |
13 |
$0.94 |
| 1160F |
|
12,179 |
9,630 |
$0.80 |
| 1159F |
|
10,643 |
8,400 |
$0.68 |
| 2022F |
|
20 |
19 |
$0.09 |
| 3072F |
|
19 |
19 |
$0.09 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
368 |
342 |
$0.00 |
| G9664 |
Patients who are currently statin therapy users or received an order (prescription) for statin therapy |
3,504 |
2,698 |
$0.00 |
| 1101F |
|
9,013 |
7,080 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
1,423 |
1,169 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,175 |
1,096 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
2,105 |
1,737 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
1,422 |
1,170 |
$0.00 |
| 1036F |
|
247 |
225 |
$0.00 |